Targeted Oncology

, Volume 4, Issue 2, pp 121–133

Renal toxicity of targeted therapies

  • Ronan J. Kelly
  • Bertrand Billemont
  • Olivier Rixe
Review

DOI: 10.1007/s11523-009-0109-x

Cite this article as:
Kelly, R.J., Billemont, B. & Rixe, O. Targ Oncol (2009) 4: 121. doi:10.1007/s11523-009-0109-x

Abstract

The use of molecular targeted therapies for the treatment of cancer has increased over the last decade. The benefits of these compounds in terms of efficacy are often relatively modest and counter balanced by the occurrence of significant toxicities. Many of these newer agents used in clinical practice lack specificity and selectivity and have a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined and numerous class-specific toxicities have been described. The kidney is an organ where most of these targeted pathways are expressed. Preclinical data and human renal biopsies have generated an understanding of the mechanisms involved in how targeted agents can cause renal toxicity. This review article discusses the observed nephrotoxicity with this burgeoning class of therapeutics and reviews both the biological reasons for its occurrence and possible ways to prevent significant renal damage.

Keywords

Targeted therapies Renal toxicity Sunitinib Bevacizumab Sorafenib 

Copyright information

© US Government 2009

Authors and Affiliations

  • Ronan J. Kelly
    • 1
  • Bertrand Billemont
    • 2
  • Olivier Rixe
    • 1
  1. 1.National Cancer Institute, Medical Oncology BranchCenter for Cancer ResearchBethesdaUSA
  2. 2.CERIA (Centre d’Etudes et de Recours sur les Inhibiteurs de l’Angiogenese)Cochin HospitalParisFrance